Pharmaceutical Analysis & Statistics in Oceania Countries, May 2013 (p10)

Talk to Louis

+1 718 618 4302

Search inside this page

You might be interested in: therapeutics, drug, cancer, more »

271-320 of about 600 reports

Purchase Reports From Reputable Market Research Publishers

New Zealand Pharmaceuticals and Healthcare Industry Update Quarter 4 2011

New Zealand Pharmaceuticals and Healthcare Industry Update Quarter 4 2011

  • $ 1 300
  • Industry report
  • September 2013
  • by Business Monitor International

BMI View: New Zealand’s pharmaceutical industry has a classic low risk, low reward profile. Multinational drugmakers are attracted to the country’s non-communicable disease burden, direct-toconsume ...

  • Industries : Drug and Medication
  • Countries : New Zealand
Australia Business Projection Industry Update Quarter 4 2011

Australia Business Projection Industry Update Quarter 4 2011

  • $ 1 208
  • Industry report
  • September 2013
  • by Business Monitor International

Core Views We believe the negative impact of the recent natural disasters in Queensland, business debt deleveraging and weakening home prices will weigh on growth, although strong export performance owing ...

  • Industries : Drug and Medication
  • Countries : Australia
Premature Ejaculation - Pipeline Review, H2 2013

Premature Ejaculation - Pipeline Review, H2 2013

  • $ 2 000
  • Industry report
  • August 2013
  • by Global Markets Direct

Premature Ejaculation - Pipeline Review, H2 2013 Summary Global Markets Direct's, 'Premature Ejaculation - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This ...

  • Industries : Pathology
  • Countries : World, Australia
Australia Pharmaceuticals and Healthcare Industry Update Quarter 4 2011

Australia Pharmaceuticals and Healthcare Industry Update Quarter 4 2011

  • $ 1 300
  • Industry report
  • August 2013
  • by Business Monitor International

BMI View: Australian prospects for multinational drugmakers are mixed. In the first quarter of the year it was announced that eight medicines would not be included in the country's Pharmaceutical Benefits ...

  • Industries : Drug and Medication
  • Countries : Australia
OTC Pharmaceuticals Market Overview in Australia

OTC Pharmaceuticals Market Overview in Australia

  • $ 350
  • Industry report
  • August 2013
  • by MarketLine

It includes data on industry size and key market segments, plus textual and graphical analysis of the major trends and drivers and key competitors, main industry players and demographic information. What's ...

  • Industries : Over-the-counter Drug
  • Countries : Australia
Online Pharmaceutical Sales in Australia - Industry Market Research Report

Online Pharmaceutical Sales in Australia - Industry Market Research Report

  • $ 890
  • Industry report
  • August 2013
  • by Ibisworld

Stable condition: Strong competition and regulatory hurdles constrain industry growth Online Pharmaceutical Sales in Australia Companies in this industry primarily sell pharmaceutical products via the ...

  • Industries : Pharmaceutical
  • Countries : Australia
Online Vitamin and Supplement Sales in Australia - Industry Market Research Report

Online Vitamin and Supplement Sales in Australia - Industry Market Research Report

  • $ 890
  • Industry report
  • August 2013
  • by Ibisworld

Growth in supplements: The industry will continue to benefit from the expanding online retail market Online Vitamin and Supplement Sales in Australia This industry includes specialist online retailers ...

  • Industries : Vitamin and Supplement
  • Countries : Australia
Squamous Non-Small Cell Lung Cancer - Pipeline Review, H2 2013

Squamous Non-Small Cell Lung Cancer - Pipeline Review, H2 2013

  • $ 2 000
  • Company report
  • July 2013
  • by Global Markets Direct

Squamous Non-Small Cell Lung Cancer - Pipeline Review, H2 2013 Summary Global Markets Direct's, 'Squamous Non-Small Cell Lung Cancer - Pipeline Review, H2 2013', provides an overview of the indication's ...

  • Industries : Pathology
  • Countries : World, United States, New Zealand, Australia
Nausea - Pipeline Review, H2 2013

Nausea - Pipeline Review, H2 2013

  • $ 2 000
  • Company report
  • July 2013
  • by Global Markets Direct

Nausea - Pipeline Review, H2 2013 Summary Global Markets Direct's, 'Nausea - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information ...

  • Industries : Therapy
  • Countries : World, Australia, United States, Japan
Biovail Laboratories International SRL - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Biovail Laboratories International SRL - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • July 2013
  • by Global Data

Summary Biovail Laboratories International SRL is engaged in developing, manufacturing, and selling pharmaceutical products and licenses its intellectual property.The company is headquatered in Barbados. ...

  • Industries : Drug Delivery Technology
  • Countries : Canada, Barbados, Australia, World, United States, North America
Emergency Contraception Market Analysis in New Zealand

Emergency Contraception Market Analysis in New Zealand

  • $ 898
  • Industry report
  • July 2013
  • by Euromonitor International

Euromonitor International's report offers a comprehensive guide to the size and shape of the industry at a national level. It provides the latest retail sales data from 2006 to 2010 , allowing you to ...

  • Industries : Drug and Medication
  • Countries : New Zealand
Ear Care Market Analysis in New Zealand

Ear Care Market Analysis in New Zealand

  • $ 898
  • Industry report
  • July 2013
  • by Euromonitor International

Ear care in New Zealand was stagnating in 2010, with no special or unique growth drivers. Euromonitor International's report offers a comprehensive guide to the size and shape of the industry at a national ...

  • Industries : Drug and Medication
  • Countries : New Zealand
photonamic GmbH & Co. KG - Pharmaceuticals & Healthcare - Deals and Alliances Profile

photonamic GmbH & Co. KG - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • July 2013
  • by Global Data

Summary photonamic GmbH and Co. KG (Photonamic) is a medical device company. The company develops 5-aminolevulinic acid in the field of fluorescence diagnosis and photodynamic therapy. Its product is Gliolan, ...

  • Industries : Pharmaceutical
  • Countries : Australia, World
Australian Pharmaceutical Industries Ltd in Retailing (Australia)

Australian Pharmaceutical Industries Ltd in Retailing (Australia)

  • $ 153
  • Company report
  • July 2013
  • by Euromonitor International

Australian Pharmaceutical Industries Ltd is planning for rapid expansion in Australia, with the aim of opening at least 400 Priceline stores by 2014. This target amounts to an expansion of up to 50% from ...

  • Industries : Pharmaceutical
  • Countries : Australia
Zuellig Australia Pharmacy Services Pty Ltd in Retailing (Australia)

Zuellig Australia Pharmacy Services Pty Ltd in Retailing (Australia)

  • $ 153
  • Company report
  • July 2013
  • by Euromonitor International

Zuellig Australia Pharmacy Services Pty Ltd is committed to investing in its core business of healthcare in order to help this business grow through organic business expansion. The company is also prepared ...

  • Industries : Pharmacies and Drug Stores, E-commerce
  • Countries : Australia
Vascular Closure Systems, Inc. - Product Pipeline Analysis, 2013 Update

Vascular Closure Systems, Inc. - Product Pipeline Analysis, 2013 Update

  • $ 750
  • Company report
  • July 2013
  • by Global Data

Summary Vascular Closure Systems, Inc (VCS) is a medical device company. The company develops and commercializes vascular access closure technology for the interventional cardiology market. It develops ...

  • Industries : Drug Discovery and Development
  • Countries : United States, Philippines, New Zealand, Australia, Singapore
Vitamin and Supplement Stores in Australia - Industry Market Research Report

Vitamin and Supplement Stores in Australia - Industry Market Research Report

  • $ 890
  • Industry report
  • July 2013
  • by Ibisworld

Healthy growth: Increasing health consciousness and sports participation will enhance industry performance Vitamin and Supplement Stores in Australia This industry consists of physical stores that mainly ...

  • Industries : Vitamin and Supplement
  • Countries : Australia
iNova Pharmaceuticals (Symbol:Australia) SWOT Analysis, Strategy, Revenues and Profits

iNova Pharmaceuticals (Symbol:Australia) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • July 2013
  • by Global Data

This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in ...

  • Industries : Pharmaceutical
  • Countries : Australia
Taisho Pharmaceutical Co., Ltd. (Symbol:4535) SWOT Analysis, Strategy, Revenues and Profits

Taisho Pharmaceutical Co., Ltd. (Symbol:4535) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • July 2013
  • by Global Data

This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in ...

  • Industries : Pharmaceutical
  • Countries : Japan, Philippines, United States, Asia, Australia, Indonesia
Australian Pharmaceutical Industries Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

Australian Pharmaceutical Industries Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

  • $ 350
  • Company report
  • June 2013
  • by MarketLine

Project Synopsis: MarketLine's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken ...

  • Industries : Pharmaceutical
  • Countries : Australia
New Zealand Pharmaceuticals Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

New Zealand Pharmaceuticals Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

  • $ 350
  • Company report
  • June 2013
  • by MarketLine

Project Synopsis: MarketLine's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken ...

  • Industries : Pharmaceutical
  • Countries : New Zealand
Brodalumab (Psoriasis) - Forecast and Market Analysis to 2022

Brodalumab (Psoriasis) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • May 2013
  • by Global Data

Brodalumab (Psoriasis) - Forecast and Market Analysis to 2022 Summary Psoriasis is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2-3% worldwide ...

  • Industries : Pathology
  • Countries : World, Brazil, Spain, Italy, France, Germany, Japan, Australia, Europe, United States, United Kingdom, China
Pegasys (Hepatitis C Virus) - Forecast and Market Analysis to 2022

Pegasys (Hepatitis C Virus) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • May 2013
  • by Global Data

Pegasys (Hepatitis C Virus) - Forecast and Market Analysis to 2022 Summary Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease ...

  • Industries : Pathology
  • Countries : World, Brazil, Spain, Italy, France, Germany, Japan, United States, Australia, Europe, United Kingdom, China
Secukinumab (Psoriasis) - Forecast and Market Analysis to 2022

Secukinumab (Psoriasis) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • May 2013
  • by Global Data

Secukinumab (Psoriasis) - Forecast and Market Analysis to 2022 Summary Psoriasis is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2-3% worldwide ...

  • Industries : Pathology
  • Countries : World, Brazil, Spain, Italy, France, Germany, Japan, Australia, Europe, United States, United Kingdom, China
PegIntron (Hepatitis C Virus) - Forecast and Market Analysis to 2022

PegIntron (Hepatitis C Virus) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • May 2013
  • by Global Data

PegIntron (Hepatitis C Virus) - Forecast and Market Analysis to 2022 Summary Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The ...

  • Industries : Pathology
  • Countries : World, Brazil, United States, Spain, Italy, France, Germany, Japan, Australia, Europe, United Kingdom, China
Ixekizumab (Psoriasis) - Forecast and Market Analysis to 2022

Ixekizumab (Psoriasis) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • May 2013
  • by Global Data

Ixekizumab (Psoriasis) - Forecast and Market Analysis to 2022 Summary Psoriasis is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2-3% worldwide ...

  • Industries : Pathology
  • Countries : World, Brazil, Spain, Italy, France, Germany, Japan, Australia, Europe, United States, United Kingdom, China
Copegus and Rebetol (Hepatitis C Virus) - Forecast and Market Analysis to 2022

Copegus and Rebetol (Hepatitis C Virus) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • May 2013
  • by Global Data

Copegus and Rebetol (Hepatitis C Virus) - Forecast and Market Analysis to 2022 Summary Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. ...

  • Industries : Pathology
  • Countries : World, Brazil, Spain, Italy, France, Germany, Japan, United States, Australia, Europe, United Kingdom, China
Tildrakizumab (Psoriasis) - Forecast and Market Analysis to 2022

Tildrakizumab (Psoriasis) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • May 2013
  • by Global Data

Tildrakizumab (Psoriasis) - Forecast and Market Analysis to 2022 Summary Psoriasis is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2-3% worldwide ...

  • Industries : Pathology
  • Countries : World, Brazil, Spain, Italy, France, Germany, Japan, United States, Australia, Europe, United Kingdom, China
Incivek (Hepatitis C Virus) - Forecast and Market Analysis to 2022

Incivek (Hepatitis C Virus) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • May 2013
  • by Global Data

Incivek (Hepatitis C Virus) - Forecast and Market Analysis to 2022 Summary Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease ...

  • Industries : Pathology
  • Countries : World, Brazil, Spain, Italy, France, Germany, Japan, United States, Australia, Europe, United Kingdom, China
Xeljanz (Psoriasis) - Forecast and Market Analysis to 2022

Xeljanz (Psoriasis) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • May 2013
  • by Global Data

Xeljanz (Psoriasis) - Forecast and Market Analysis to 2022 Summary Psoriasis is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2-3% worldwide (Perera ...

  • Industries : Pathology
  • Countries : Germany, Japan, World, Brazil, Spain, Italy, France, United States, Australia, Europe, United Kingdom, China

13 Companies

Read our Company Profiles

GlaxoSmithKline P.L.C.

United States

Johnson and Johnson

United States

Management Strategies

United States

Abbott Laboratories

United States

Medtronic Inc.

United States

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.